Compare Charles River Laboratories Intl. Inc (CRL) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Fox Corp Class A — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Fox Corp Class A trades at $54.84 (market cap $21.85B). The key difference: Fox Corp Class A is the larger of the two by market cap, and Fox Corp Class A pays a 1.02% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | FOXA | |
|---|---|---|
Market Cap | $11.14B | $21.85B |
Sector | Health | Media |
52-Week High | $233.60 | $76.11 |
52-Week Low | $145.57 | $48.79 |
Enterprise Value | $14.00B | $25.83B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FOXA trades at $55.9, up 3.29% today, with a bearish technical signal but strong fundamental performance including three consecutive quarterly earnings beats. Revenue grew to $16.3B in 2025, with net income margin expanding to 13.88%. The company's acquisition of Roku for $22 billion marks a strategic pivot into streaming distribution, though it introduces leverage risk.
The outlook is mixed: analyst consensus targets $67.80 (21% upside) with a 50/50 buy/hold split, but 2026 forecasts show declining cash flow and earnings. Key risks include integration challenges from the Roku deal and streaming competition. Upside hinges on successful execution of the new strategy and advertising momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
